SCHEMBL5836646

SCHEMBL5836646

COc1ccc(Oc2ccc(-c3ncc(-c4ccccc4)o3)cc2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.68
ALDH1A1 P00352 3/20 0.68
HPGD P15428 3/20 0.68
SMN1; SMN2 Q16637 2/20 0.68
TSHR P16473 2/20 0.68
ALOX15 P16050 1/20 0.68
CASP1 P29466 1/20 0.68
PTPN1 P18031 10/20 0.67
PTPN2 P17706 2/20 0.64
RAB9A P51151 4/20 0.59
MEN1 O00255 1/20 0.59
MITF O75030 1/20 0.59
KMT2A Q03164 1/20 0.59
NPC1 O15118 3/20 0.58
PTPN6 P29350 1/20 0.56
LMNA P02545 2/20 0.55
MAPT P10636 1/20 0.55
MAPK1 P28482 1/20 0.55
HTT P42858 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5836178 1.00 KDM4E (0.68) KDM4EALDH1A1HPGDSMN1; SMN2TSHR
SCHEMBL4875222 0.95 TSHR (0.74) KDM4EALDH1A1HPGDSMN1; SMN2TSHR
SCHEMBL10909733 0.95 TSHR (0.74) KDM4EALDH1A1HPGDSMN1; SMN2TSHR
SCHEMBL1180905 0.89 KDM4E (0.72) KDM4EALDH1A1HPGDSMN1; SMN2TSHR
SCHEMBL5836382 0.85 PTPN1 (0.71) KDM4EALDH1A1HPGDSMN1; SMN2TSHR
SCHEMBL5837406 0.85 PTPN1 (0.71) KDM4EALDH1A1HPGDSMN1; SMN2TSHR
SCHEMBL2949331 0.83 TSHR (0.59) KDM4EALDH1A1HPGDSMN1; SMN2TSHR
SCHEMBL1180099 0.82 KDM4E (0.68) KDM4EALDH1A1HPGDSMN1; SMN2TSHR
SCHEMBL75219 0.82 ALOX15 (1.00) KDM4EALDH1A1HPGDSMN1; SMN2TSHR
SCHEMBL10726923 0.82 ALOX15 (1.00) KDM4EALDH1A1HPGDSMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7119201-B2 Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors PFIZER INC (US) 2006-10-10 US disclosed
EP-1501515-B1 TRIARYL-OXY-ARYLOXY-PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS PFIZER PROD INC (US) 2005-11-02 EP disclosed
US-20040006057-A1 Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors PFIZER PRODUCTS INC. 2004-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006057-A1 Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors MMP8, MMP9, MMP1 KDM4E 1926/4885ALDH1A1 300/4885HPGD 288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.